Abbott Cardiovascular Systems, Inc.

Dade Behring Marburg Gmbh

Syntex (u.s.a.) Inc.

Behringwerke Aktiengesellschaft

Dade Behring Inc.

Advanced Cardiovascular Systems, Inc.

Siemens Healthcare Diagnostics Gmbh

Siemens Healthcare Diagnostics Products Gmbh

Dariush Davalian

Edwin F Ullman

Syed F A Hossainy

Florian Ludwig

Stephen D Pacetti

Jinping Wan

John Joseph Stankus

Katsuyuki Murase

Mikael Trollsas

Michael H Ngo

Paul M Consigny

Syed F Hossainy

Marcel R Pirio

Irina Astafieva

Rajendra Singh

Maureen H Beresini

David C Gale

Syed Faiyaz Ahmed Hossainy

Boris Anukhin

Cheng-I Lin

Denise Leah Williams

Yunbing Wang

Ronald W Heil, Jr

Kyle Klein

John E Papp

Nurith Kurn

Benjamyn Serna

Jesus Magana

Mae W Hu

Fozan El-Nounou

Jeffrey T Ellis

Joel Harrington

Svetlana Alexander

Daniel B Wagner

Li Zhao

Rachel Bright

Mary C Ericson

Carl N Skold

Florian Niklas Ludwig

Hshiou-ting Liu

Remy Cromer

Hao-Ming Hsiao

Paul Levi Miller

Yuet Mei Khong

Rohan Peries

Syed Fayaiz Ahmed Hossainy

Kenneth Cornell Kasper

Henry Jeong

Steve De Keczer

Mae Wan-Leng Hu

Kesavan Radika

James Su

William E Webler, Jr

O Mikael Trollsas

Erik David Eli

Sophia L Wong

Kimchi Tran

Joshua Smith

Yen Ping Liu

Troy Carter

Charles Silvis

Adrain Gale

Jacqueline Sadakan Ishkanian

Evan Norton

Michael Huy Ngo

Ronald A Farnbach

Barbara Stamberg

Dudley S Jayasinghe

Joshua Takeshi Smith

This invention relates to photodynamic therapy (PDT) of vulnerable plaque using two pluralities of nanoparticles, one plurality comprising a PDT agent that is sensitive to blue-green light wherein the nanoparticles are capable of penetrating only into the fibrous cap of the vulnerable plaque and one plurality comprising a PDT agent that is sensitive to red light wherein the nanoparticles are capable of penetrating into the core of the vulnerable plaque.

Drug delivery system and method of treatment of vascular diseases using photodynamic therapy

A polymeric stent can be implanted for treatment of the Eustachian tube. The stent can be designed to have length-dependent radial strength to allow it to stay within the Eustachian tube and to allow normal closing and opening of the Eustachian tube. A balloon can be used to implant the stent, and the balloon can be coated with a therapeutic agent. A coated balloon can also be used to transfer therapeutic agents to the sinus cavity during a balloon sinus dilation procedure.

Devices and methods for treatment of the Eustachian tube and sinus cavity

A medical device includes a polymer scaffold crimped to a catheter having an expansion balloon. The scaffold has a structure that produces a low late lumen loss when implanted within a peripheral vessel and also exhibits a high axial fatigue life. In a preferred embodiment the scaffold forms ring structures interconnected by links, where a ring has 12 crowns and at most two links connecting adjacent rings.

Polymer scaffolds for peripheral vessels

Nano-constructs comprising nanoshells and methods of using the nano-constructs for treating or ameliorating a medical condition are provided.

Nanoshells on polymers

A bioabsorbable polymeric stent with time dependent structure and properties and methods of treating a diseased blood vessel with the bioabsorable polymeric stent are disclosed. The structure and properties of the stent change with time and allow the vessel to be restored to a natural unstented state. The bioabsorbable stent loses mechanical integrity in a controlled manner due to modification of selected structural elements.

Method of treatment with a bioabsorbable stent with time dependent structure and properties and regio-selective degradation

A composition of bioactive agent-loaded micelles with tissue-targeting properties and methods of using the same are disclosed.

Bioactive agent-loaded targeting micelles

Bioabsorbable scaffolds are disclosed with a rigid polymer component and a rubbery polymer component. The rubbery polymer component is miscible, partially miscible, or immiscible with the rigid polymer component.

Rubber toughened bioresorbable polymer peripheral scaffolds

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region or a perivascular site, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (apo A-I) synthetic peptide, or combination of an apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various apo A-I mimetic peptides, or endogenous apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous apo A-I.

Sustained release of Apo A-I mimetic peptides and methods of treatment

The current invention is directed to compositions comprising a plurality of particles including nanoshells or a medical device with a coating including nanoshells allowing for triggered drug release. Methods of treatment with such compositions are also included.

Drug delivery compositions including nanoshells for triggered drug release

The present invention relates to the regional delivery of therapeutic agents for the treatment of vascular diseases wherein regional delivery refers to delivery of a therapeutically effective amount of the therapeutic agent to an area of the vessel that includes not only afflicted tissue but non-afflicted tissue at the periphery of the afflicted tissue as well.

Regional delivery of therapeutic agents for the treatment of vascular diseases

This invention is directed to a method of treating a vascular disease involving administration to a patient by means of an angioplasty balloon a composition comprising a permeability-enhancing substance and a therapeutic agent.

Blood vessel permeability-enhancement for the treatment of vascular diseases

A method of modifying a medical device such as a stent with nano-constructs is disclosed. The method comprises applying a first fluid to the stent; immersing the stent being wet from the first fluid into a second fluid having a suspension of nano-constructs; and removing the stent from the second fluid and allowing the first and second fluid to be removed such that the nano-constructs are carried by the stent for in vivo application of the constructs to a target location of a mammalian subject. The nano-constructs can be attached to the surface of the stent, can be attached to a surface of the coating of the stent, can be embedded into the stent, or can be embedded into the coating.

Medical devices containing biobeneficial particles

A method including advancing a delivery device through a lumen of a blood vessel to a particular region in the blood vessel; and introducing a composition including a sustained-release carrier and an apolipoprotein A-I (Apo A-I) synthetic mimetic peptide into a wall of the blood vessel at the particular region, wherein the peptide has a property that renders the peptide effective in reverse cholesterol transport. A composition including an apolipoprotein A-I (Apo A-I) synthetic peptide, or combination of an Apo A-I synthetic mimetic peptide and an Acyl CoA cholesterol: acyltransferase (ACAT) inhibitor in a form suitable for delivery into a blood vessel, the peptide including an amino acid sequence in an order reverse to an order of various Apo A-I mimetic peptides, or endogenous Apo A-I analogs, or a chimera of helix 1 and helix 9 of endogenous Apo A-I.

Sustained release of APO A-I mimetic peptides and methods of treatment

Compositions that contain bioactive agent-loaded nanoparticles with heart targeting capabilities and methods of using the same for the treatment of disease are disclosed.

Bioactive agent-loaded heart-targeting nanoparticles

This invention relates to the targeted delivery of hydrophobic drugs or combinations of hydrophobic drugs with photodynamic therapy agents to vascular lesions by complexation of the drugs to blood serum lipoproteins, which have an affinity for and accumulate in such vascular lesions.

Method of targeting hydrophobic drugs to vascular lesions

Growing community of inventors

San Jose, CA, United States of America

Dariush Davalian